Dulaglutide vs Tirzepatide

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Dulaglutide vs Tirzepatide: they're closely matched on evidence (7 vs 7.8/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Too Close to Call

Dulaglutide and Tirzepatide are closely matched across evidence, studies, and safety.

Dulaglutide1 win

Tirzepatide1 win

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Dul7.0

Dulaglutide

Too few graded studiesLimited safety

Tir7.8

Tirzepatide

Too few graded studiesLimited safety

Evidence

Evidence Score

7/10

Studies: 143

Meta-analyses: 15

Level: Strong

Evidence Score

Best7.8/10

Studies: 133

Meta-analyses: 42

Level: Strong

Research findings

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies106
Weight managementToo few graded studies18
Cardiovascular outcomesToo few graded studies18

Verdict

Too few graded studies

Top outcomes

Weight managementToo few graded studies80
Glycemic & metabolic controlToo few graded studies53
Heart & blood pressureToo few graded studies20

Shared outcomes (3)

Outcomes where both Dulaglutide and Tirzepatide have evidence — compare verdict strength side-by-side.

Weight managementToo few graded studies18Too few graded studies80
Glycemic & metabolic controlToo few graded studies106Too few graded studies53
Heart & blood pressureToo few graded studies18Too few graded studies20

Dosage & timing

Recommended Dosage:

Prescription-only, clinician-prescribed. Subcutaneous 0.75 mg once weekly to start, usually escalated to 1.5 mg; 3.0 mg and 4.5 mg once-weekly doses are available for additional glycemic lowering. DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: dulaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Risk of gallbladder disease (gallstones, cholecystitis).
Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common, especially during dose escalation.
Weight loss is real but modest and includes some loss of lean mass — pair sustained weight loss with resistance training and adequate protein.
Avoid COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.
Not for cosmetic weight loss without a genuine medical indication.
May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Subcutaneous once-weekly pen (Trulicity)

Recommended Dosage:

Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.
Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.
A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.
FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.
Not for cosmetic or off-label use without a medical indication and supervision.
May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.
Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Once-weekly subcutaneous injection (Mounjaro / Zepbound)

Safety

Limited safetyTie

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Insulin and sulfonylureas (moderate)
Oral medications (general) (moderate)

Side Effects:

NauseaVomiting / diarrheaGallbladder disease (cholelithiasis / cholecystitis)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Limited safetyTie

Drug Interactions:

Oral contraceptives (moderate)
Insulin and sulfonylureas (moderate)
Oral medications generally (moderate)

Side Effects:

NauseaDiarrheaVomiting

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple endocrine neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Shared goals

Manage weightTirzepatide

Dulaglutide52/100

Tirzepatide90/100

Manage blood sugarTirzepatide

Dulaglutide82/100

Tirzepatide85/100

What you'll notice

🩸 Improved glycemic controlpositive

Weeks to months

❤️ Reduced cardiovascular eventspositive

Months to years

⚖️ Modest weight losspositive

Months

🤢 GI adverse effects (very common)trade-off

Especially during initiation/escalation

🩸 Strong glycemic controlpositive

Weeks to months

⚖️ Large weight losspositive

Months (dose-escalated over ~20 weeks)

😴 Reduced sleep-apnea severitypositive

Weeks to months

🤢 GI side effects (common)negative

Mostly during titration

Key studies

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Lancet (2019) · Rct · n=9901

Multicentre, double-blind, placebo-controlled cardiovascular-outcomes RCT: 9,901 patients aged ≥50 with type 2 diabetes, randomized to subcutaneous dulaglutide 1.5 mg/week or placebo at 371 sites in 24 countries

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Lancet Diabetes Endocrinol (2019) · Meta analysis

Meta-analysis of seven GLP-1 receptor agonist cardiovascular-outcomes trials (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6); 56,004 participants

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Lancet (2019) · Rct · n=9901

Pre-specified exploratory analysis of the REWIND trial (9,901 participants) examining the renal component of the composite microvascular outcome

All Dulaglutide studies

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

N Engl J Med (2021) · Rct · n=1879

Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg

Tirzepatide Once Weekly for the Treatment of Obesity.

N Engl J Med (2022) · Rct · n=2539

72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

N Engl J Med (2025) · Rct · n=751

Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide

All Tirzepatide studies

Frequently asked questions

Is Dulaglutide better than Tirzepatide?

Both Dulaglutide and Tirzepatide are closely matched — the best choice depends on your specific health goals.

Is Dulaglutide or Tirzepatide better for manage weight?

For manage weight, Tirzepatide has a higher relevance score (90 vs 52).

Can I take Dulaglutide and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Dulaglutide vs Semaglutide Dulaglutide vs Liraglutide AREDS2 Formula vs Dulaglutide Semaglutide vs Tirzepatide Liraglutide vs Tirzepatide Thiamine vs Tirzepatide

Still deciding between Dulaglutide and Tirzepatide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Dulaglutide details Tirzepatide details

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: dulaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Risk of gallbladder disease (gallstones, cholecystitis).

Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common, especially during dose escalation.

Weight loss is real but modest and includes some loss of lean mass — pair sustained weight loss with resistance training and adequate protein.

Avoid COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.

Not for cosmetic weight loss without a genuine medical indication.

May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.

Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.

A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.

FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.

Not for cosmetic or off-label use without a medical indication and supervision.

May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.

Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Frequently asked questions

Is Dulaglutide better than Tirzepatide?

Both Dulaglutide and Tirzepatide are closely matched — the best choice depends on your specific health goals.

Is Dulaglutide or Tirzepatide better for manage weight?

For manage weight, Tirzepatide has a higher relevance score (90 vs 52).

Can I take Dulaglutide and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.